Compare AstraZeneca plc (AZN) vs IQIYI Inc - ADR (IQ) Price & Performance

AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.

The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.

iQIYI (IQ) trades at $1.13 with no recent price movement, showing mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported Q1 2026 revenue decline of 13% year-over-year to $915.2M, missing expectations, though it beat EPS estimates. Valuation metrics show a high P/E ratio of 144.05 but attractive P/S of 0.29 and P/B of 0.57. Recent leadership changes and AI platform expansion highlight strategic shifts amid challenging fundamentals.

The outlook remains cautious with declining revenues and negative profitability margins creating headwinds. Analyst consensus leans bullish with 50% buy ratings, but execution risks and competitive pressures in China's streaming market pose significant challenges. The stock's current valuation disconnect between high P/E and low price-to-sales metrics suggests potential for recovery if AI initiatives drive growth, but near-term volatility is expected.